HIGHLIGHTS
- who: Viviana Lo Buono and collaborators from the (UNIVERSITY) have published the Article: Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy, in the Journal: Medicina 2022, 551 of 17/04/2022
- what: The authors aimed to identify possible cognitive peculiarities or atypical symptoms in the first signs of PML.
SUMMARY
Natalizumab is a humanized monoclonal antibody against integrin beta-4 with highly effective therapy for relapsing-remitting MS. A few cases of PML in MS patients have been described in individuals treated with other agents including dimethyl fumarate . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.